Roche Diagnostics Corporation, a subsidiary of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has named Matthew Sause as its new president and chief executive officer, North America, effective 4 November 2019.

The position is based at the company's North American headquarters in Indianapolis.

Sause joins the company from Gilead Sciences, where he was senior vice president and head of Global Commercial Product Strategy. Earlier, Sause had a 17-year career with the Roche Group. In the Diagnostics division at Roche from 2002-14, Sause's experience included United States-based sales roles in Molecular Diagnostics, commercial operations positions in Asia, and country leadership in Ireland. In the Pharmaceuticals division from 2014-19, Sause served as president of Country Operations in Peru and Korea before becoming vice president and lifecycle leader for Roche's cancer medicine Tecentriq, a global role based at Genentech, member of the Roche Group, in South San Francisco. Sause succeeds Jack Phillips, who left Roche Diagnostics at the end of August.